Aisling Capital Management LP
Source: SEC Form 13F · as of Mar 2026Aisling Capital Management LP holds 8 biotech & pharma companies tracked by BioSniper, totaling $414.0M in value as of Mar 2026 (SEC Form 13F).
Companies held
8
Total value held
$414.0M
BioSniper AIPage evidence connected
Prepared research question
What matters most for BridgeBio Pharma, Inc. (BBIO)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| BBIOBridgeBio Pharma, Inc. | 5,089,611 | $378.0M |
| BCAXBicara Therapeutics Inc. | 568,919 | $11.3M |
| BBOTBridgeBio Oncology Therapeutics, Inc. | 1,018,018 | $9.1M |
| CMPSCOMPASS Pathways plc | 1,432,336 | $7.9M |
| SRRKScholar Rock Holding Corp | 77,031 | $3.8M |
| BMEABiomea Fusion, Inc. | 2,048,757 | $3.1M |
| MRKRMarker Therapeutics, Inc. | 325,370 | $423K |
| OKUROnKure Therapeutics, Inc. | 88,607 | $367K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.